Send to

Choose Destination
See comment in PubMed Commons below
J Clin Neurol. 2005 Oct;1(2):107-20. doi: 10.3988/jcn.2005.1.2.107. Epub 2005 Oct 20.

Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Author information

  • 1Committees on Neurobiology and Molecular Medicine, Departments of Neurology and Neurobiology, Pharmacology, & Physiology, The University of Chicago, USA.


Despite successful treatment of Parkinson's disease (PD) with a wide variety of symptomatic therapy, the disease continues to progress and drug-resistance symptoms become the predominant factors producing the disability of PD patients. Neuroprotective therapies have been tested, but clinically effective drugs have not been found yet. New insights gained from studies of genetic forms of PD point to the common pathogenic mechanisms that have been suspected in sporadic forms of the disease and may provide new approaches for the future neuroprotective therapies.


Genetics; Neuroprotection; Parkinson's disease; Pathogenesis

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Neurological Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk